Business Monitor International


Iran Pharmaceuticals & Healthcare Report

Published 02 December 2014

  • 118 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Iran Pharmaceuticals & Healthcare Report

BMI View:   BMI continues to adjust its forecasts for Iran's pharmaceutical market to account for the sanction-induced currency crisis and high rates of inflation. The rapid depreciation of the rial means that we expect the value of the market to contract sharply in US dollar terms. While improved international relations have reduced the regulatory risk associated with operating in the market for multinational drugmakers, the recent proclamation of the Islamic State (IS) in neighbouring Iraq and Syria increases the threat of political instability .

Headline Expenditure Projections

  • Pharmaceuticals: IRR44,216bn (USD2.46bn) in 2013 to IRR51,684bn (USD1.63bn) in 2014; +16.9% in local currency terms and -33.9% in US dollar terms.

  • Healthcare: IRR548,672bn (USD16.63bn) in 2013 to IRR617,190bn (USD19.41bn) in 2014; +12.5% in local currency terms and +16.7% in US dollar terms.

Risk/Reward Index

BMI considers Iran's business environment to be slightly less appealing than the previous quarter, with a score of 41.5 out of 100 in Q115, unchanged from the previous quarter. Due to reappraisals of the scores of other countries, Iran's position in the regional rankings improved three places in the regional rankings to 14th out of 30 countries in the Middle East and Africa in Q115. Its overall score is below the regional average of 42.3. Generally speaking, Iran benefits from a large and growing population and relatively widespread access to healthcare services. However, its regulatory regime - including intellectual property (IP) rights, political and economic situation - is highly questionable. Consequently, the country performs above the regional average for potential rewards and below the regional average in terms of risk.

Key Trends And Developments

  • In October 2014, India-based generic drugmaker Cipla signed an agreement with its existing Iranian distributor to set up a manufacturing facility in Iran, according to a stock market disclosure.

  • Iran's pharmaceutical...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2010-2018)
18
Healthcare Market Forecast
19
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2010-2018)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2010-2018)
21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2010-2018)
21
Prescription Drug Market Forecast
22
Patented Drug Market Forecast
23
Generic Drug Market Forecast
23
OTC Medicine Market Forecast
24
Pharmaceutical Trade Forecast
25
Table: Pharmaceutical Trade Data And Forecasts (Iran 2012-2018)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2012-2018)
29
Other Healthcare Data
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
32
Table: Iran - Economic Activity
36
Industry Risk Reward Ratings
37
Middle East & Africa Risk/Reward Ratings
37
Iran Risk/Reward Ratings
45
Rewards
45
Risks
45
Market Overview
47
Industry Trends And Developments
49
Epidemiology
49
Table: HIV/AIDS Prevalence In Iran
51
Healthcare Sector
52
Healthcare Insurance
54
International Healthcare Collaboration
55
Traditional Herbal Remedies
56
Research & Development
57
Biotechnology
58
Clinical Trials
60
Regulatory Development
61
Intellectual Property Regime
63
Counterfeit Medicines
64
Pricing And Reimbursement
65
Competitive Landscape
67
Pharmaceutical Sector
67
Domestic Pharmaceutical Sector
68
Table: Leading Drug Manufacturers, Iranian Year To March 20, 2009
68
Pharmaceutical Wholesale
72
Table: Leading Distributors, Iranian Year To March 20 2008
72
Pharmaceutical Retail Sector
73
Company Profile
74
Darou Pakhsh
74
Caspian Tamin Pharmaceutical Company
77
Pharmieco
80
Pars Darou
82
Zahravi Pharmaceutical Company
84
Amin Pharmaceutical Company
87
Sina Darou Pharmaceutical Company
89
Exir Pharmaceuticals
91
Novartis
93
Merck & Co
95
Pfizer
97
GlaxoSmithKline
99
Sanofi
101
Demographic Forecast
103
Table: Iran's Population By Age Group, 1990-2020 ('000)
104
Table: Iran's Population By Age Group, 1990-2020 (% of total)
105
Table: Iran's Key Population Ratios, 1990-2020
106
Table: Iran's Rural And Urban Population, 1990-2020
106
Glossary
107
Methodology
109
Pharmaceutical Expenditure Forecast Model
109
Healthcare Expenditure Forecast Model
109
Notes On Methodology
110
Risk/Reward Ratings Methodology
111
Ratings Overview
112
Table: Pharmaceutical Risk/Reward Ratings Indicators
112
Indicator Weightings
113

The Iran Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Iran Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Iran pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Iran, to test other views - a key input for successful budgeting and strategic business planning in the Iranian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Iranian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Iran.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc